Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Products under Development by Stage of Development | 8 | 1 |
| Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Products under Development by Therapy Area | 9 | 1 |
| Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Products under Development by Indication | 10 | 2 |
| Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Products under Development by Companies | 14 | 2 |
| Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Products under Development by Universities/Institutes | 16 | 2 |
| Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Therapeutics Assessment | 18 | 6 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 2 |
| Assessment by Route of Administration | 21 | 2 |
| Assessment by Molecule Type | 23 | 1 |
| Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Companies Involved in Therapeutics Development | 24 | 8 |
| AnaBios Corporation | 24 | 1 |
| Astellas Pharma Inc. | 25 | 1 |
| AstraZeneca Plc | 26 | 1 |
| Flex Pharma, Inc. | 27 | 1 |
| Glenmark Pharmaceuticals Ltd. | 28 | 1 |
| Hydra Biosciences, Inc. | 29 | 1 |
| Johnson &Johnson | 30 | 1 |
| Pila Pharma AB | 31 | 1 |
| Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Drug Profiles | 32 | 18 |
| ASP-7663 Drug Profile | 32 | 1 |
| AZ-465 Drug Profile | 33 | 1 |
| FLX-787 Drug Profile | 34 | 4 |
| GRC-17536 Drug Profile | 38 | 2 |
| HX-100 Drug Profile | 40 | 2 |
| hydralazine hydrochloride Drug Profile | 42 | 1 |
| JNJ-41477670 Drug Profile | 43 | 1 |
| Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders Drug Profile | 44 | 1 |
| Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia Drug Profile | 45 | 1 |
| Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System Drug Profile | 46 | 2 |
| Small Molecules to Block TRPA1 and TRPV1 for Pain Drug Profile | 48 | 1 |
| Small Molecules to Block TRPA1 and TRPV1 for Pain and Inflammation Drug Profile | 49 | 1 |
| Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Dormant Projects | 50 | 1 |
| Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Discontinued Products | 51 | 1 |
| Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Featured News &Press Releases | 52 | 11 |
| Jun 15, 2016: Flex Pharma Initiates Phase 2 Efficacy Study in Multiple Sclerosis | 52 | 1 |
| May 25, 2016: Flex Pharma Initiates Human Efficacy Study with Single Molecule Tablet in Nocturnal Leg Cramps | 52 | 1 |
| Apr 19, 2016: Flex Pharma s Positive Human NLC Study Selected for Presentation at AAN Annual Meeting | 53 | 1 |
| Mar 14, 2016: Flex Pharma Positive Human NLC Study Selected for Late-Breaking Presentation at AAN Annual Meeting | 54 | 1 |
| Feb 02, 2016: Flex Pharma Announces Positive Human Efficacy in Nocturnal Leg Cramp Study | 55 | 1 |
| Jan 06, 2016: Hydra Biosciences to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 11 | 56 | 1 |
| Jan 06, 2016: Enrollment Completed in Flex Pharma s Exploratory Human Nocturnal Leg Cramp Study | 56 | 1 |
| Nov 10, 2015: Flex Pharma Announces FLX-787 as Clinical Drug Candidate | 57 | 1 |
| Oct 20, 2015: Flex Pharma Demonstrates Single Agent Efficacy and Dose Response in Reducing Human Muscle Cramps | 58 | 1 |
| Jul 28, 2015: Flex Pharma Announces Two Poster Presentations at Upcoming Scientific Meetings | 58 | 1 |
| Jul 07, 2015: Flex Pharma Announces Reduction of Muscle Cramping in Athletes | 59 | 1 |
| May 04, 2015: NSF Approves Flex Pharma s Proprietary Formulation under NSF s Certified for Sport Program | 60 | 1 |
| Apr 27, 2015: Flex Pharma Initiates Human Proof-of-Concept Efficacy Study in Nocturnal Leg Cramps | 60 | 1 |
| Apr 14, 2015: Hydra Biosciences Receives Approval from Health Canada to Begin Phase 1 Trial for HX-100 | 61 | 1 |
| Feb 18, 2015: AAN Selects Flex Pharma Data for Oral Platform Presentation | 61 | 2 |
| Appendix | 63 | 2 |
| Methodology | 63 | 1 |
| Coverage | 63 | 1 |
| Secondary Research | 63 | 1 |
| Primary Research | 63 | 1 |
| Expert Panel Validation | 63 | 1 |
| Contact Us | 63 | 1 |
| Disclaimer | 64 | 1 |